ASX Announcements

16-09-19 – Change of Director’s Interest Notice – Appendix 3Y

16-09-19 – Issue of Shares and Appendix 3B

30/08/2019 – Appendix 4E and Annual Financial Report FY 2019

30/08/2019 – Appendix 4G and Corporate Governance Statement FY 2019

26/08/19 – Plexoval Exosome Wound Healing Human Study Starts

19/08/2019 – Appendix 3Y. Change of Director’s Interest Notice

19/08/2019 – Appendix 3B. New Issue Announcement

16/08/2019 – Closure of Offer Under the Share Purchase Plan

13/08/2019 – Application for Quotation of Additional Securities and Agreement

08/08/2019 – Notice of General Meeting

01/08/2019 – Issue of Placement Shares

29/07/2019 – EX1 ASX Announcement – Upcoming Release of Shares from Escrow

25/07/2019 – Share Purchase Plan (SPP) Offer Document

25/07/2019 – Cleansing Statement – Notice under ASIC Class Order [CO 09/425]

25/07/2019 – Exopharm Appendix 4C – June Quarter

24/07/2019 – Investor Deck Placement and Share Purchase Plan

24/07/2019 – Share Placement and Share Purchase Plan Announcement

22/07/2019 – Exopharm Secures Ethics Approval for the Plexoval Clinical Trial

22/07/2019 – Trading Halt

19/07/2019 – Appendix 3B New Issue Announcement

05/07/2019 – Escrow Release

23/05/2019 – Upcoming Release of Shares from Escrow

22/05/2019 – Acceleration of Development Activities

30/04/2019 – March 2019 Quarterly Activities Report and Appendix 4C

09/04/2019 – Investor Presentation

01/04/2019 – April 2019 Market Update

27/03/2019 – Explainer: The critical bottleneck of exosome isolation and the power of Exopharm’s LEAP technology

21/02/2019 – Dec 2018 Half-Yearly Report and Appendix 4D

05/02/2019 – Positive outcomes from initial animal studies of Plexaris and Exomeres

31/01/2018 – January 2019 Quarterly Cash Flow Report

31/01/2019 – December 2018 Quarterly Activities Report